Recombinant hypoallergenic Equ c 1 polypeptides for use in the immunotherapy of horse allergy
AssigneeDesentum Oy
InventorsJuha Rouvinen, Kristiina Takkinen, Marja-Leena Laukkanen, Merja Niemi, Janne Jänis, Jaana Haka
Life of this patent
Estimating the term…
Abstract
The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.
Claims24
A recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen, wherein said amino acid modifications are amino acid substitutions at positions defined by the Equ c 1 wild type sequence of SEQ ID NO:1, wherein said polypeptide comprises at least one first amino acid substitution at a first position selected from the group consisting of:
- E21 and V47, and at least one second amino acid substitution at a second position selected from the group consisting of:
- V110 and F112.
(canceled)
A method of producing a recombinant hypoallergenic Equ c 1 polypeptide for immunotherapy comprising the steps of:
- a) modifying nucleic acid sequence encoding a wild type Equ c 1 polypeptide in order to substitute at least two amino acids at positions defined by the Equ c 1 wild type sequence of SEQ ID NO:1, wherein the nucleic acid sequence encoding a wild type Equ c 1 polypeptide is modified so that at least one first amino acid substitution is formed at a first position selected from the group consisting of:
- E21 and V47, and at least one second amino acid substitution is formed at a second position selected from the group consisting of:
- V110 and F112;
- and
- b) expressing or producing the recombinant Equ c 1 polypeptide from the modified nucleic acid;
- and
- c) isolating and purifying the recombinant Equ c 1 polypeptide from step b).
24-26. (canceled)
Dependencies are inferred from the claim text.